Brief: Denali Therapeutics Says Informed By Sanofi That K2 Phase 2 Study Was Discontinued Based On Not Meeting Primary And Key Secondary Endpoints
10/10/2024 21:12
Oct 10 (Reuters) - Denali Therapeutics Inc DNLI.O :
* DENALI THERAPEUTICS- INFORMED BY SANOFI THAT K2 PHASE 2
STUDY
WAS DISCONTINUED BASED ON NOT MEETING PRIMARY AND KEY SECONDARY
ENDPOINTS
Source text for Eikon: ID:n0001714899-24-000205
Further company coverage: DNLI.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers